Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
16471
post-template-default,single,single-post,postid-16471,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Home > Blogs  > Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

12 Jun Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Posted at 10:45h in Blogs by

In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% patients (A). Intracranial tumor shrinkage was also seen (B). The median duration of response was 8.5 months (95% CI 6.2 to 13.8), the median PFS was 6.5 months (95% CI, 4.7 to 8.4) and the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). The results were similar to sotorasib.
(Ref: Jänne PA et al. N Engl J Med. June 3, 2022)
#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6941618273817894912

No Comments

Sorry, the comment form is closed at this time.